title: [Recommendations for the use of methotrexate in patients with juvenile idiopathic arthritis].
abstract: OBJECTIVE
  To develop a consensus document of recommendations for the use of methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA).
  
  
  METHODS
  A group of eleven experts proposed several clinical questions on the use of MTX in patients with JIA. A systematic review was conducted and the evidence and recommendations for each question were extracted. The results were discussed and validated by the experts in a work session to establish the final recommendations.
  
  
  RESULTS
  MTX is recommended as the first drug for inducing remission in JIA, and its indication should be made according to the clinical category of the patient. Prior to treatment, it is recommended to perform a complete blood count, including white cells, levels of liver enzymes, serum creatinine, and other analytical parameters according to specific risk factors. Treatment should be initiated with a dose of 10-15 mg/m(2)/week. In cases of uveitis or polyarthritis, an initial dose of 15 mg/m(2)/week should be considered. For a better bioavailability and tolerability, it is preferable to administer MTX parenterally if the dose is ≥15 mg/m(2)/week. It is necessary to periodically perform an analytical monitoring of the patient and to assess possible alterations in liver enzymes to make changes if necessary. Combinations with biological agents may be necessary, as well as the concomitant addition of folic or folinic acid.
  
  
  CONCLUSIONS
  This document describes the main recommendations for the appropriate use of MTX in JIA patients, according to scientific evidence and clinical experience.
authors.affiliation: Hospital Universitario y Politécnico La Fe, Valencia, España. Electronic address: calvo_inm@gva.es.
authors.forename: I
authors.initials: I
authors.lastname: Calvo
authors.affiliation: Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues de Llobregat, Barcelona, España.
authors.forename: J
authors.initials: J
authors.lastname: Antón
authors.affiliation: Hospital Infantil Universitario Niño Jesús, Madrid, España.
authors.forename: J C
authors.initials: JC
authors.lastname: López Robledillo
authors.affiliation: Hospital Universitario 12 de Octubre, Madrid, España.
authors.forename: J
authors.initials: J
authors.lastname: de Inocencio
authors.affiliation: Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: M L
authors.initials: ML
authors.lastname: Gamir
authors.affiliation: Hospital Universitario La Paz, Madrid, España.
authors.forename: R
authors.initials: R
authors.lastname: Merino
authors.affiliation: Hospital Son Espases, Palma de Mallorca, España.
authors.forename: L
authors.initials: L
authors.lastname: Lacruz
authors.affiliation: Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: M
authors.initials: M
authors.lastname: Camacho
authors.affiliation: Hospital Universitario Cruces, San Vicente de Barakaldo, España.
authors.forename: M J
authors.initials: MJ
authors.lastname: Rua
authors.affiliation: Hospital Universitario de Canarias, San Cristóbal de La Laguna , Santa Cruz de Tenerife, España.
authors.forename: S
authors.initials: S
authors.lastname: Bustabad
authors.affiliation: Hospital Materno Infantil del Hospital Regional Universitario de Málaga, Málaga, España.
authors.forename: G
authors.initials: G
authors.lastname: Díaz Cordovés-Rego
mesh_terms: D001168:Arthritis / Q000188:drug therapy; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001772:Blood Cell Count; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D012307:Risk Factors; D014605:Uveitis / Q000188:drug therapy
chemical_list: D008727:Methotrexate
keywords: Artritis idiópatica juvenil; Consenso; Consensus; Juvenile idiopathic arthritis; Methotrexate; Metotrexato